<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title> Considerations for the Design and Interpretation of Noninferiority Trials</title>

<script src="site_libs/header-attrs-2.22/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cerulean.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.13.2/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<link href="site_libs/pagedtable-1.1/css/pagedtable.css" rel="stylesheet" />
<script src="site_libs/pagedtable-1.1/js/pagedtable.js"></script>
<link href="site_libs/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="site_libs/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>









<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">Zehui Bai</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="index.html">
    <span class="fa fa-home"></span>
     
    Home
  </a>
</li>
<li>
  <a href="Clinical_Experience.html">
    <span class="fa fa-user"></span>
     
    Clinical Experience
  </a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-pencil-square-o"></span>
     
    Study Design
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="ZB-Design_Dose-Escalation-and-Stratification-Designs.html">Dose Escalation and Stratification Designs in Early Oncology Development</a>
    </li>
    <li>
      <a href="ZB-Design_Phase-I-Trials---Design-Considerations.html">Phase I Trials - Design Considerations</a>
    </li>
    <li>
      <a href="ZB-Design_Phase-II-Trials---Design-Considerations.html">Phase II Trials - Design Considerations</a>
    </li>
    <li>
      <a href="ZB-Design_Phase-III-Trials---Design-Considerations.html">Phase III Trials - Design Considerations</a>
    </li>
    <li>
      <a href="ZB-Design_Phase-IV-Trials---Design-Considerations.html">Phase IV Trials - Design Considerations for Post Marketing Surveillance</a>
    </li>
    <li>
      <a href="ZB-Design_Design-and-Monitoring-of-Adaptive-Clinical-Trials.html">Design and Monitoring of Adaptive Clinical Trials</a>
    </li>
    <li>
      <a href="ZB-Design_Design-and-Evaluation-of-Complex-Sequential-Trials.html">Design and Evaluation of Complex Sequential Analysis Trials</a>
    </li>
    <li>
      <a href="ZB-Design_Design-and-Evaluation-of-Diagnostic-Study.html">Design and Evaluation of Diagnostic Study</a>
    </li>
    <li>
      <a href="ZB-Design_Externally-Controlled-Trials.html">Considerations for the Design and Conduct of Externally Controlled Trials</a>
    </li>
    <li>
      <a href="ZB-Design_Bioequivalence-and-Biosimilar-Trials.html">Bioequivalence and Biosimilar Trials</a>
    </li>
    <li>
      <a href="ZB-Design_Exploring-Survival-Analysis-Designs-for-Clinical-Trials.html">Exploring Survival Analysis Designs for Clinical Trials</a>
    </li>
    <li>
      <a href="ZB-Design_Projecting-How-Long-Your-Trial-Will-Take.html">Projecting How Long Your Trial Will Take</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-sliders"></span>
     
    Sample Size
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="ZB-SSC_Everything-to-Know-About-Sample-Size-Determination.html">Everything to Know About Sample Size Determination</a>
    </li>
    <li>
      <a href="ZB-SSC_Choosing-the-Effect-Size-for-Sample-Size-Calculations.html">Choosing the Effect Size</a>
    </li>
    <li>
      <a href="ZB-SSC_Sample-Size-and-Power-for-Non-Parametric-Analysis.html">Sample Size and Power for Non-Parametric Analysis</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-line-chart"></span>
     
    Data Visualization
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="ZB-Plot_Adverse-Event.html">Adverse Event Visualization</a>
    </li>
  </ul>
</li>
<li>
  <a href="cv.html">
    <span class="fa fa-file-pdf-o"></span>
     
    CV
  </a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="mailto:zehuibai@outlook.com">
    <span class="fa fa-envelope-o"></span>
     
    Contact me
  </a>
</li>
<li>
  <a href="https://github.com/Zehuibai">
    <span class="fa fa-github"></span>
     
    GitHub
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore"><p><img src="logo.png"
style="width:3in" /><br />
Considerations for the Design and Interpretation of Noninferiority
Trials</p></h1>

</div>


<div id="introduction" class="section level1">
<h1>Introduction</h1>
<p>Non-inferiority clinical trials are designed to determine if a new
treatment is not significantly worse than an established treatment, in
terms of efficacy or other clinically relevant outcomes. These trials
are particularly useful when it’s considered unethical to use a placebo
because an effective standard treatment already exists.</p>
<div id="design-of-non-inferiority-trials" class="section level2">
<h2>Design of Non-Inferiority Trials</h2>
<ol style="list-style-type: decimal">
<li><p><strong>Establishing the Non-Inferiority Margin
(“Delta”):</strong> Before the trial begins, researchers must define a
margin of difference that is considered clinically acceptable. This
margin, known as the delta, is crucial because it represents the maximum
allowable difference in efficacy between the new treatment and the
standard treatment where the new treatment would still be considered
acceptable.</p></li>
<li><p><strong>Statistical Considerations:</strong> Unlike superiority
trials where researchers prove one treatment is better than another,
non-inferiority trials aim to show that the new treatment is not
significantly worse than the control. Statistically, this involves
demonstrating that the efficacy of the new treatment falls within the
pre-specified delta from the standard treatment.</p></li>
<li><p><strong>Confidence Intervals:</strong> The results of
non-inferiority trials are often expressed in terms of confidence
intervals. A common approach is to use a one-sided 97.5% confidence
interval or a two-sided 95% confidence interval for the difference
between the treatment effects. If this interval does not include the
delta, the new treatment can be considered not inferior to the standard
treatment.</p></li>
</ol>
<p><img src="02_Plots/INF_Intro.png" /> <em>Source: Mauri L,
D’Agostino RB Sr. Challenges in the Design and Interpretation of
Noninferiority Trials. N Engl J Med. 2017 Oct 5;377(14):1357-1367. doi:
10.1056/NEJMra1510063. PMID: 28976859.</em></p>
</div>
<div id="essential-components" class="section level2">
<h2>Essential Components</h2>
<p>Noninferiority trials are a key type of clinical study when it’s
unethical to use a placebo due to the availability of effective
treatments. Here’s a breakdown of the essential components of
noninferiority study designs, as outlined in a Table below:</p>
<p><img src="02_Plots/INF_Features.png" /> <em>Source: Mauri L,
D’Agostino RB Sr. Challenges in the Design and Interpretation of
Noninferiority Trials. N Engl J Med. 2017 Oct 5;377(14):1357-1367. doi:
10.1056/NEJMra1510063. PMID: 28976859.</em></p>
<ol style="list-style-type: decimal">
<li><p><strong>Foundation on Prior Evidence</strong>: Noninferiority
trials are predicated on existing randomized trials that have
demonstrated the superiority of the active control over a placebo. This
historical evidence sets the baseline efficacy expected from the active
treatment.</p></li>
<li><p><strong>Endpoint Selection and Expected Performance</strong>: The
endpoint for the trial is selected based on the active control’s
performance in prior studies. This helps establish what outcomes can be
anticipated from the active control in the absence of the experimental
treatment.</p></li>
<li><p><strong>Noninferiority Margin Definition</strong>: During the
design phase, a noninferiority margin is defined. This margin, typically
a percentage of the effect size observed in placebo-controlled trials,
represents the smallest effect size that would be clinically acceptable
for the new treatment compared to the active control. The margin ensures
that the new treatment preserves a meaningful proportion of the active
treatment’s effect.</p></li>
<li><p><strong>Comparator Considerations and Assay Sensitivity</strong>:
The trial must distinguish effectively between effective and ineffective
treatments. Assay sensitivity is crucial; the trial design should allow
the active control to demonstrate its superiority to a hypothetical
placebo. This often poses challenges since placebo groups are ethically
precluded in such setups.</p></li>
<li><p><strong>Constancy Assumption</strong>: The trial’s design should
maintain the conditions under which the active control was previously
shown to be effective. This includes the use of a consistent metric for
evaluating treatment effects, such as relative risk, odds ratio, or
absolute risk difference. Changes in these metrics can significantly
impact the power and validity of the trial conclusions.</p></li>
<li><p><strong>Trial Execution and Outcome Ascertainment</strong>:
Rigorous execution and accurate outcome measurement are critical.
Inaccuracies such as loss to follow-up, treatment crossover, or
subjective outcome measures can make treatments appear more similar than
they are, potentially leading to erroneous conclusions.</p></li>
<li><p><strong>Analytical Considerations</strong>: Noninferiority trials
often require different analytical approaches compared to superiority
trials. While superiority trials commonly use intention-to-treat
analysis, noninferiority studies might need per-protocol analysis to
avoid bias, especially if not all participants adhere to the assigned
treatment. Analyzing both datasets and ensuring consistency across them
is advisable to avoid false positive results.</p></li>
</ol>
</div>
<div id="challenges-and-complexities" class="section level2">
<h2>Challenges and Complexities</h2>
<p>Noninferiority trial designs present specific challenges that require
careful consideration, especially in the absence of a placebo group.
Here are some of the special challenges involved:</p>
<ol style="list-style-type: decimal">
<li><p><strong>Implicit Superiority Basis</strong>: Noninferiority
trials inherently rely on an implicit comparison of the test treatment’s
efficacy against a placebo, even though a placebo group is not included.
This is based on historical data demonstrating the superiority of the
active control over placebo.</p></li>
<li><p><strong>Use of Historical Controls</strong>: When ethical or
practical concerns prevent the inclusion of a placebo group, historical
data must be used to establish the superiority of the active control.
This can be problematic when such historical data are lacking or
outdated, making it difficult to set a reliable noninferiority
margin.</p></li>
<li><p><strong>Substitute Comparators</strong>: In situations where no
direct placebo data are available, less effective or older treatments
are often used as stand-ins. For example, in stroke prevention studies,
aspirin has been used as a comparator to set noninferiority margins for
newer anticoagulants against warfarin. Similarly, bare-metal stents and
medical therapies have served as references in trials for new
drug-eluting stents and surgical interventions, respectively.</p></li>
<li><p><strong>Sample Size and Noninferiority Margin</strong>: Setting
the noninferiority margin based on what can be statistically
distinguished with a given sample size (back-calculating) rather than
what is clinically meaningful can compromise the validity of the trial
conclusions. The sample size should be adequate to ensure that the
noninferiority margin reflects true clinical equivalence or
acceptability.</p></li>
<li><p><strong>Misinterpretation of Superiority Trials as
Noninferiority</strong>: It is incorrect to conclude noninferiority from
a superiority trial that fails to show a significant difference due to
lack of power (small sample size). The adage “absence of evidence is not
evidence of absence” is particularly relevant here. Trials that are
underpowered may not detect small but clinically significant
differences, which could lead to erroneous conclusions if interpreted as
evidence of noninferiority.</p></li>
<li><p><strong>Challenges with Meta-Analysis</strong>: While
meta-analysis can be a useful tool to increase power and aggregate
findings from multiple studies, relying on it to overcome the
limitations of underpowered individual studies can be misleading. Issues
such as heterogeneity among studies and potential statistical biases
make meta-analysis a less reliable substitute for well-powered,
well-designed randomized trials.</p></li>
</ol>
<p><img src="02_Plots/INF_Sup%20and%20Int.png" /> <em>Source: Mauri L,
D’Agostino RB Sr. Challenges in the Design and Interpretation of
Noninferiority Trials. N Engl J Med. 2017 Oct 5;377(14):1357-1367. doi:
10.1056/NEJMra1510063. PMID: 28976859.</em></p>
</div>
<div id="evaluation-of-aafety" class="section level2">
<h2>Evaluation of Aafety</h2>
<p>Evaluating safety through noninferiority study designs presents
unique challenges, particularly when determining what constitutes an
acceptable level of risk for adverse events, as these are not typically
quantifiable with the same precision as efficacy outcomes.</p>
<ol style="list-style-type: decimal">
<li><p><strong>Determining Safety Margins</strong>: In efficacy trials,
noninferiority margins can be based on historical data where the effect
of the control is well established. For safety, however, such benchmarks
are less clear because there may not be historical data that
definitively establish a ‘safe’ level of adverse events. Safety margins
often require subjective judgment from clinical advisors on what level
of risk is acceptable, taking into consideration the severity and
frequency of adverse events, the overall risk to the patient population,
and the expected benefits of the treatment.</p></li>
<li><p><strong>Example from the PRECISION Trial</strong>: The PRECISION
trial, which assessed the safety of celecoxib compared to naproxen and
ibuprofen in treating arthritis, illustrates these challenges. A
relative margin of 1.33 was chosen based on an expected 2% annualized
risk for significant cardiovascular events. This margin was designed to
ensure that celecoxib’s risk did not exceed that of naproxen by an
unacceptable amount, reflecting both the direct comparison with
competitors and the absence of a placebo.</p></li>
<li><p><strong>Noninferiority and Placebo Control</strong>: The
PRECISION trial, like many safety studies, couldn’t use a placebo
control because withholding effective pain relief would be unethical.
Consequently, the trial could not demonstrate that the risk of
cardiovascular events with celecoxib, naproxen, or ibuprofen was
equivalent to a non-treatment scenario.</p></li>
<li><p><strong>Extending Noninferiority to Safety Evaluations</strong>:
While the framework for noninferiority efficacy trials can be adapted to
safety studies, doing so involves significant challenges. The concept of
a prespecified margin, while still useful, requires careful
consideration and justification in the context of safety, where the
outcomes have direct and significant impacts on patient health.</p></li>
</ol>
</div>
<div id="new-trial-methods-and-their-effect" class="section level2">
<h2>New Trial Methods and Their Effect</h2>
<p>The evolving methodologies in clinical trial designs, particularly
noninferiority studies, reflect a response to both practical and
scientific challenges, aiming to streamline the process while
maintaining the integrity and reliability of the findings.</p>
<ol style="list-style-type: decimal">
<li><p><strong>Simplification of Trial Conduct</strong>: Simplifying the
operational aspects of clinical trials, such as reducing the frequency
of participant contacts and the number of outcomes assessed, enhances
both noninferiority and superiority trials. This approach tends to allow
for the collection of more reliable data from a larger sample size and
reduces potential biases associated with missing data. By streamlining
procedures, trials can become more efficient and less burdensome,
potentially improving participant retention and the quality of the data
collected.</p></li>
<li><p><strong>Pragmatic Trials and Routine Data Collection</strong>:
Pragmatic trials, which often utilize routine clinical care settings for
data collection, can introduce specific challenges for noninferiority
studies. Issues such as imbalances in treatment adherence and
inaccuracies in endpoint determination are particularly problematic in
noninferiority settings where the objective is to prove that the new
intervention is not substantially worse than the existing standard.
These factors can skew the results and make it difficult to draw
definitive conclusions about noninferiority.</p></li>
<li><p><strong>Patient Involvement in Trial Design</strong>:
Incorporating patient input into the design of noninferiority trials is
increasingly recognized as valuable. Patients’ preferences and insights
can inform the determination of acceptable safety margins and the
overall acceptability of risks versus benefits. This approach aligns
with the principles of shared decision-making in clinical practice,
enhancing the relevance and patient-centeredness of the study
outcomes.</p></li>
<li><p><strong>Application in Comparative Effectiveness
Research</strong>: Noninferiority studies are particularly useful in
comparative effectiveness research and health services research within
the framework of value-based healthcare. By evaluating clinical outcomes
and costs separately, these studies can ensure that treatment
efficiencies do not compromise clinical efficacy. This dual focus helps
in assessing whether newer treatments provide similar outcomes at
reduced costs or with other practical benefits.</p></li>
<li><p><strong>Use of Observational and Meta-Analysis Data</strong>:
Beyond traditional randomized trials, observational studies and
meta-analyses are increasingly being used to test noninferiority
hypotheses. The prespecification of hypotheses and noninferiority
margins is crucial in these contexts to enhance the credibility and
validity of the results. These methodologies allow for the analysis of
larger datasets and can provide additional insights into the
effectiveness of interventions in more diverse real-world
settings.</p></li>
<li><p><strong>Equivalence Studies for Biologics</strong>: Equivalence
studies, particularly in the biologics sector, have adopted
methodologies that test for both noninferiority and nonsuperiority. This
is often part of demonstrating biosimilarity, where a biologic agent is
tested against an already approved agent to confirm that it does not
significantly differ in terms of safety and efficacy. These studies are
critical for regulatory approvals and market entry of
biosimilars.</p></li>
</ol>
</div>
<div id="improving-noninferiority-trials" class="section level2">
<h2>Improving Noninferiority Trials</h2>
<p>Improving noninferiority trials involves refining various aspects of
their design, reporting, and analysis to ensure that these studies can
reliably demonstrate that new treatments are acceptably similar in
efficacy and safety to established treatments. Here are some specific
recommendations to enhance the rigor and credibility of noninferiority
trials:</p>
<ol style="list-style-type: decimal">
<li><strong>Justification of the Noninferiority Margin</strong>:
<ul>
<li><strong>Explicit Justification</strong>: The noninferiority margin
should be explicitly justified in the study design. This involves
defining how much worse the new treatment can be compared to the
standard treatment without losing its value. Justification should be
based on clinical significance rather than purely statistical
reasons.</li>
<li><strong>Incorporating Decision Analysis</strong>: Utilizing decision
analysis techniques can help in determining the noninferiority margin by
considering both population-level impacts and policy implications.</li>
<li><strong>Patient-Centered Approaches</strong>: Engaging patients
through questionnaires or interviews about their perceptions of
acceptable risk and benefit can ground the noninferiority margin in
real-world expectations and enhance the patient relevance of the trial
outcomes.</li>
</ul></li>
<li><strong>Caution with Composite Endpoints</strong>:
<ul>
<li><strong>Assessing Component Relevance</strong>: Composite endpoints,
while useful in capturing a broad spectrum of treatment effects, can
sometimes include components that do not align well with each other in
terms of their benefits and risks. It is essential to carefully select
these endpoints to ensure they are clinically coherent and
meaningful.</li>
<li><strong>Disparate Impact Evaluation</strong>: Evaluating the
disparate impacts of the components of composite endpoints on the
overall study conclusion is crucial. This involves analyzing whether any
component disproportionately affects the trial’s outcome, potentially
skewing the results.</li>
</ul></li>
<li><strong>Handling of Missing Data</strong>:
<ul>
<li><strong>Avoidance and Minimization</strong>: Strategies should be
employed from the study design phase to minimize missing data, such as
ensuring follow-up ease and patient engagement.</li>
<li><strong>Sensitivity Analyses</strong>: Implementing sensitivity
analyses to understand the impact of missing data on the trial’s
conclusions is crucial. Techniques like multiple imputation can be used
to handle missing data, providing a more robust analysis and helping to
maintain the integrity of the trial outcomes.</li>
</ul></li>
<li><strong>Enhanced Reporting Standards</strong>:
<ul>
<li><strong>Following CONSORT Guidelines</strong>: Adhering to the
CONSORT guidelines for noninferiority trials ensures that all critical
elements of the trial design, conduct, and analysis are transparently
reported.</li>
<li><strong>Regulatory Guidance Compliance</strong>: Complying with the
specific standards set forth by regulatory bodies such as the FDA and
the European Medicines Agency can enhance the validity and acceptability
of the trial results.</li>
</ul></li>
<li><strong>Continuous Review and Adaptation</strong>:
<ul>
<li><strong>Incorporating New Evidence</strong>: Noninferiority trials
should be adaptable to new scientific evidence and changes in clinical
practice that might affect the trial’s context.</li>
<li><strong>Feedback Integration</strong>: Ongoing feedback from
clinical practitioners, patients, and regulatory reviewers should be
integrated into trial protocols to refine approaches and address
emerging challenges.</li>
</ul></li>
</ol>
<p><img src="02_Plots/INF_Recommendation.png" /> <em>Source: Mauri L,
D’Agostino RB Sr. Challenges in the Design and Interpretation of
Noninferiority Trials. N Engl J Med. 2017 Oct 5;377(14):1357-1367. doi:
10.1056/NEJMra1510063. PMID: 28976859.</em></p>
</div>
</div>
<div id="reference" class="section level1">
<h1>Reference</h1>
<ul>
<li>Mauri L, D’Agostino RB Sr. Challenges in the Design and
Interpretation of Noninferiority Trials. N Engl J Med. 2017 Oct
5;377(14):1357-1367. doi: 10.1056/NEJMra1510063. PMID: 28976859.</li>
</ul>
</div>



</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
